88 / 144
88
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Referências
1. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H: A randomized
trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic
macular edema: baseline features. Retina. 2008;28:919-930.
2. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Fried-
man SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial
evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt
laser for diabetic macular edema. Ophthalmology. 2010;117:1064-70.
3. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li
XY, Hollander DA, Schiffman RM, Whitcup SM. Dexamethasone intravitreal implant in
combination with laser photocoagulation for the treatment of diffuse diabetic macular
edema. Ophthalmology. 2013; 120: 1843-1851.
4. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H,
Hashad Y, Whitcup SM. Three-year, randomized, sham-controlled trial of dexametha-
sone intravitreal implant in patients with diabetic macular edema. Ophthalmology.
2014;121:1904-1914.
5. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD,
Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexametha-
sone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-86.
6. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis
RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K, FAME Study
Group: Sustained delivery `uocinolone Acetonid Vitreous Implants:Long-Term Bene%t
in Patients with Chronic Diabetic Macular Edema . Ophthalmology. 2014;121: 1892-
1903.
7. Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A Nonrandomized,
Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN in
Chronic Diabetic Macular Edema Patients Considered Insuf%ciently Responsive to
Available Therapies (RESPOND). Ophthalmic Research – published on-line February 9,
2017.
8. Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Ef%cacy and Safety of sustained-
-delivery `uocinolone acetonide intravitreal implant in patients with chronic diabetic
macular edema insuf%ciently responsive to available therapies: a real-life study. Clin
Ophthalmol. 2016;10:1257-1264.
9. Quhill H, Quhill F. Real–Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid
Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation. Case
Rep Ophthalmol. 2016;7:301-307.
10. Wykoff C, Chakravarthy U, Campochiaro P, Bailey C, Green K, Cunha -Vaz J. Long-
-Term Effects of Intravitreal 0,19 mg Fluocinolone Acetonide Implant on Progression
and Regression of Diabetic Retinopathy. Ophthalmology. 2017 Apr;124(4):440-449.
doi: 10.1016/j.ophtha.2016.11.034. Epub 2017 Jan 9.
11. Campochiaro PA, Ha%z G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner
L, Sabates N, Billman K, Kapik B, Green K, Kane F. Sustained ocular delivery of `uoci-
nolone acetonide by an intravitreal insert. Ophthalmology. 2010; 117: 1393-1399.
12. Avery RL, Gordon GM: Systemic safety of prolonged monthly anti-vascular endothelial
growth factor therapy for diabetic macular edema: a systematic review and meta-analy-
sis. JAMA Ophthalmol. 2016; 134: 21-29.